Tip os
Log ind
IMG_0813_Henrik500_jpg.jpg
Foto: ALK-Abelló/PR - Henrik Jacobi, forskning og udviklingsdirektør

ALK readies new EU application for allergy tablet

Top picks in English:

Allergy drug maker ALK is ready to initiate talks with European authorities about the launch of a treatment against a common allergy that is brought to new regions by changes in the global climate.


BY LOUISE WENDT JENSEN
Offentliggjort 06.09.16 kl. 14:35

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Novo’s R&D chief: Semaglutide wins out every time

Mads Krogsgaard Thomsen Top picks in English:

Novo Nordisk's major pipeline hope semaglutide has bested pretty much every major diabetes drug on the market in head-to-head studies, says CSO Mads Krogsgaard Thomsen. But the group will still have to beat out two more products before the GLP-1 analogue can be seen as the king of the clinic.

Zealand carries out USD 89m IPO in the US

Top picks in English:

Zealand Pharma has listed on the Nasdaq Global Select Market in addition to its listing in Copenhagen, raising USD 89 in the process. But the move does not mean the biotech company has lost faith in the Danish investor base, says CEO Britt Meelby Jensen.

Danish hearing aid giants in global showdown

Top picks in English:

The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Darzalex is still the “star of the show” for Genmab

Top picks in English:

Genmab’s Darzalex royalties now cover the company’s operating costs and in addition to that, the cancer drug continues its expansion to new markets. And according to CEO, Jan van de Winkel, Genmab could potentially raise its guidance this year.

Philips absorbs Danish acquisition after massive deficit

Top picks in English:

Following a year with massive deficit, Danish company Biocell now merges with parent corporation Philips, and its leading product is divested.

Forsiden lige nu

Ambu planlægger stor investering i salgsstyrken

larsmarcher.jpg Medico & Rehab:

Den danske medicokoncern Ambu oplever stadigt stigende vækstrater, som selskabet endda vil løfte yderligere. Det skal blandt andet ske med den måske største enkeltinvestering i Ambus historie, siger adm. direktør Lars Marcher.

Ambu-topchef: 2020-plan kommer til oktober

Medico & Rehab:

Det danske medicoselskab Ambu er klar med en ny, ambitiøs 2020-plan om et par måneder, afslører selskabets adm. direktør, Lars Marcher.

Medtronic leverer vækst trods IT-nedbrud

Medico & Rehab:

Et omfattende nedbrud i Medtronics globale IT-system har det seneste kvartal lagt en dæmper på væksten for medicokoncernen, som dog alligevel viser pæn fremgang på både top- og bundlinje.

Sjællandske sygehuse er klar til Sundhedsplatformen

Sygdom & Sundhed:

Ifølge en parathedsvurdering er sygehusene i Region Sjælland klar til at implementere Sundhedsplatformen som planlagt til november . Det til tider problematiske forløb i Region Hovedstaden har givet øget indsigt i processen, lyder det.

Tredje opjustering i træk: Ambu brager afsted

Medico & Rehab:

Salget hos den danske medicoproducent Ambu vokser så meget i tredje kvartal, at virksomheden nu opjusterer forventningerne for tredje gang i streg.

Bavarian slutter sig til børseliten: "Det giver god karma"

Medicinal & Biotek:

Når det toneangivende danske aktieindeks, OMX C20 Cap, til december afskaffes til fordel for det udvidede C25-indeks bliver det efter al sandsynlighed med Bavarian Nordic som en ny spiller på holdet. Og det har betydning for virksomheden - både økonomisk, omdømmemæssigt og for den interne selvopfattelse, lyder det fra analytiker og selskabet selv.

ANNONCE
ANNONCE


ANNONCE